Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

NCT ID: NCT00340834

Last Updated: 2017-09-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1292 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fingolimod 1.25 mg

Group Type EXPERIMENTAL

Fingolimod 1.25 mg

Intervention Type DRUG

Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.

Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

Fingolimod 0.5 mg

Group Type EXPERIMENTAL

Fingolimod 0.5 mg

Intervention Type DRUG

Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.

Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

Interferon β-1a 30 µg

Group Type ACTIVE_COMPARATOR

Interferon β-1a 30 µg

Intervention Type DRUG

Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.

Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fingolimod 1.25 mg

Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.

Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

Intervention Type DRUG

Fingolimod 0.5 mg

Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.

Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

Intervention Type DRUG

Interferon β-1a 30 µg

Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.

Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FTY720 FTY720

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients between ages 18-55 with a diagnosis of multiple sclerosis (MS)
* Patients with a relapsing-remitting disease course
* Patients with Expanded Disability Status Scale (EDSS) score of 0-5.5

Exclusion Criteria

* Patients with other chronic disease of the immune system, malignancies, acute pulmonary disease, cardiac failure, etc
* Pregnant or nursing women
* Patients who cannot tolerate treatment with an interferon
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmacuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

North Central Neurology Associates, PC, 1809 Kress Street

Cullman, Alabama, United States

Site Status

Barrow Neurological Institute

Phoenix, Arizona, United States

Site Status

The Neurology Center, 3907 Waring Road, Suite 3

Oceanside, California, United States

Site Status

Associated Neurologists, PC, 69 Sand Pit Road, Suite 300

Danbury, Connecticut, United States

Site Status

Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff

Fairfield, Connecticut, United States

Site Status

Yale University Multiple Sclerosis Center

New Haven, Connecticut, United States

Site Status

University of Florida Health Science Center

Jacksonville, Florida, United States

Site Status

Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1

Maitland, Florida, United States

Site Status

University of Miami, Department of Neurology

Miami, Florida, United States

Site Status

Neurological Associates

Pompano Beach, Florida, United States

Site Status

Roskamp Institute, 2040 Whitfield Ave.

Sarasota, Florida, United States

Site Status

AMO Corporation

Tallahassee, Florida, United States

Site Status

Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401

Tampa, Florida, United States

Site Status

University of South Florida, Department of Neurology

Tampa, Florida, United States

Site Status

The MS Center of Vero Beach

Vero Beach, Florida, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100

Lenexa, Kansas, United States

Site Status

University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304

St Louis, Missouri, United States

Site Status

Neuroscience and Spine Center

Charlotte, North Carolina, United States

Site Status

Raleigh Neurology Associates, 1540 Sunday Drive

Raleigh, North Carolina, United States

Site Status

Neurology & Neuroscience Associates, Inc

Akron, Ohio, United States

Site Status

Northern Ohio Neuroscience, LLC

Bellevue, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Oregon Neurology

Tualatin, Oregon, United States

Site Status

University of Pittsburgh, Department of Neurology

Pittsburgh, Pennsylvania, United States

Site Status

Absher Neurology, 274-A Commonwealth Drive

Greenville, South Carolina, United States

Site Status

Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201

Bristol, Tennessee, United States

Site Status

Advanced Neurosciences Institute

Franklin, Tennessee, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Private Practice, 3815 23rd Street

Lubbock, Texas, United States

Site Status

Integra Clinical Research, 4242 Medical Drive, Suite 6100

San Antonio, Texas, United States

Site Status

Swedish Neuroscience Institute

Seattle, Washington, United States

Site Status

Rockwood Clinic, P.S.

Spokane, Washington, United States

Site Status

West Virginia University Health Associates

Morgantown, West Virginia, United States

Site Status

Center for Neurological Disorders - Aurora St. Luke's Med Center

Milwaukee, Wisconsin, United States

Site Status

Ineba

Guarda Vieja 4435, Capital Federal, Buenos Aires, Argentina

Site Status

Fundacion Rosarina de Neurorehabilitacion

Rosario, Santa Fe Province, Argentina

Site Status

Instituto de Neurociencias de Rosario

Rosario, Santa Fe Province, Argentina

Site Status

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Site Status

Fundacion Lenox Cordoba

Córdoba, , Argentina

Site Status

Hospital J. M. Ramos Mejia

General Urquiza 609, Buenos Aires, , Argentina

Site Status

FLENI

Montaneses 2325, Buenos Aires, , Argentina

Site Status

Strategic Health Evaluators

Chatswood, New South Wales, Australia

Site Status

Royal Prince Alfred Hospital

Department of Medicine, Level, Missenden R, Camperdown, New South Wales, Australia

Site Status

Liverpool Hospital, Neurology Department, Health Services Building, 4th Floor, Goulburn and Campbell Street

Liverpool, New South Wales, Australia

Site Status

Gosford Private Hospital

North Gosford, New South Wales, Australia

Site Status

St George Private Hospital

Suite 7E, Level 5, South Street, Kogarah, New South Wales, Australia

Site Status

Box Hill Hopsital, Level 3, 16 Arnold Street

Box Hill, Victoria, Australia

Site Status

Royal Melbourne Hospital

Suite 30, Grattan St., Parkbville, Victoria, Australia

Site Status

Landesklinikum St. Poelten, Probst-Ruehrer-Str. 4

Sankt Pölten, Sankt Poelten, Austria

Site Status

Landes-Narvenklinik Wagner-Jauregg

Abteilung Fuer Neurologie, Linz, , Austria

Site Status

Universitätsklinik f. Neurologie Innsbruck

Anichstrasse 35, Innsbruck, , Austria

Site Status

Landes-Nervenklinik Christian Doppler Klinik

Ignaz Harrerstr. 79 , Salzburg, , Austria

Site Status

Evangel.Krankenh./Wien-Waehring Außenstelle

Vienna, , Austria

Site Status

Univ.-Klinik fuer Neurologie AKH

Vienna, , Austria

Site Status

Cliniques Universitaires Saint Luc

Avenue Hippocrate 10, Bruxelles, , Belgium

Site Status

UZ Brussel

Laarbeeklaan 101, Brussels, , Belgium

Site Status

Nationaal Multiple Sclerose Centrum v.z.w

Melsbroek, , Belgium

Site Status

Regionaal Ziekenhuis Sint-Trudo - Campus Sint-Jozef

Sint-Truiden, , Belgium

Site Status

Hospital Sao Rafael

Salvador, Estado de Bahia, Brazil

Site Status

Hospital das Clincas - UNICAMP

Campinas, São Paulo, Brazil

Site Status

Hospital das Clinicas da FMRPUSP

Ribeirão Preto, São Paulo, Brazil

Site Status

Irmandade da Santa Casa de Misericordia de Porto Alegre

Porto Alegre, , Brazil

Site Status

Hospital dos Servidores do Estado

Rio de Janeiro, , Brazil

Site Status

Hospital Universitario Gaffree e Guinle

Rio de Janeiro, , Brazil

Site Status

Fraser Health MS Clinic, Burnaby Hospital, 3935 Kincaid Street

Vancouver, British Columbia, Canada

Site Status

UBC MS Research, 2211 Westbrook Mall

Vancouver, British Columbia, Canada

Site Status

Nepean Medical Centre, 1 Centrepointe Drive, Suite 407

Ottawa, Ontario, Canada

Site Status

St. Michael's Hospital, Chief, Division of Neurology, 30 Bond Street,Suite 3007 - Shuter Wing

Toronto, Ontario, Canada

Site Status

Centre Hospitalier Universitaire de Sherbrooke, 3001 12th Avenue North

Fleurimont, Quebec, Canada

Site Status

Charles Lemoyne Hospital

Greenfield Park, Quebec, Canada

Site Status

CHUM - Hopital Notre-Dame

Montreal, Quebec, Canada

Site Status

Montreal Neurological Institute, 3801 University Street

Montreal, Quebec, Canada

Site Status

The Ottawa General Hospital, 501 Smyth Rd.

Ottawa, , Canada

Site Status

Private Clinic, 48 Sidi Gaber St.

Alexandria, , Egypt

Site Status

35, Dokki St., Apt. 4

Cairo, , Egypt

Site Status

Al Azhar University, 11 Talaat Harb St, Fourth Floor, Apt 18

Cairo, , Egypt

Site Status

Private Clinic, 35 Dokki St., Apt. 4

Cairo, , Egypt

Site Status

Private Clinic, 7 Batal Ahmed Abdelaziz St Abdeen

Cairo, , Egypt

Site Status

Hopital La Timone Cpcet, Rue Jean Moulin

Marseille, , France

Site Status

Hopital Central, 29 Avenue du Marechal de Lattre de Tassigny

Nancy, , France

Site Status

Hôpital Pellegrin

Place Amélie Raba Léon, Bordeaux Cedex, , France

Site Status

Hopital De Purpan

Place Du Dr. Baylac, Toulouse Cedex, , France

Site Status

Centre Hospitalier de Poissy, 10 rue du Champ Gaillard

Poissy, , France

Site Status

Hoppital Pasteur, Archet II, 30 avenue de la Voie

Romaine, , France

Site Status

Investigational Site

Bamberg, , Germany

Site Status

Investigational Site

Berlin, , Germany

Site Status

Investigational Site

Berlin, , Germany

Site Status

Investigational Site

Bremen, , Germany

Site Status

Investigational Site

Buchholz, , Germany

Site Status

Investigational Site

Cologne, , Germany

Site Status

Investigational Site

Dresden, , Germany

Site Status

Investigational Site

Düsseldorf, , Germany

Site Status

Investigational Site

Erbach/Odenwald, , Germany

Site Status

Investigational Site

Essen, , Germany

Site Status

Investigational Site

Freiburg im Breisgau, , Germany

Site Status

Investigational Site

Greifswald, , Germany

Site Status

Investigational Site

Hamburg, , Germany

Site Status

Investigational Site

Hanover, , Germany

Site Status

Investigational Site

Heidelberg, , Germany

Site Status

Investigational Site

Hennigsdorf, , Germany

Site Status

Investigational Site

Lengerich, , Germany

Site Status

Investigational Site

Mainz, , Germany

Site Status

Investigational Site

München, , Germany

Site Status

Investigational Site

München, , Germany

Site Status

Investigational Site

Potsdam, , Germany

Site Status

Investigational Site

Teupitz, , Germany

Site Status

Investigational Site

Trier, , Germany

Site Status

Investigational Site

Tübingen, , Germany

Site Status

Investigational Site

Ulm, , Germany

Site Status

Investigational Site

Ulm, , Germany

Site Status

Investigational Site

Wermsdorf, , Germany

Site Status

Investigational Site

Würzburg, , Germany

Site Status

Univ. Hospital of Heraklion

Voutes, Heraklion, Crete, Greece

Site Status

Errikos Dinan General Hospital, 107 Mesogion Ave.

Athens, , Greece

Site Status

General Hospital of Athens G. Gennimatas, 154 Mesogeion Ave.

Athens, , Greece

Site Status

Metropolitan Hospital, Ethnarchou Makariou 6 & Eleftheriou Venizelou 1

Athens, , Greece

Site Status

General University Hospital of Patra-RIO

Patra - RIO, , Greece

Site Status

Ahepa University General Hospital of Thessaloniki, 1 Stilp. Kyriakidi Str.

Thessaloniki, , Greece

Site Status

Debreceni Egyetem Orvos es Egszstd. Centr.

Debrecen, , Hungary

Site Status

Petz Aladár Megyei Oktató Kórház

Győr, , Hungary

Site Status

Veszprem Megyei Csolnoky Ferenc Korhaz

Korhaz U. 1, Veszprem, , Hungary

Site Status

Pecsi Tudomanyegyetem Neurologiai Klinika

Pécs, , Hungary

Site Status

Peterfy Sandor u. Hospital, Neurology

U. 8-20m, Budapest, , Hungary

Site Status

Uzsoki korhaz

Uzsoki U. 29., Budapest, , Hungary

Site Status

Azienda Sanitaria Osp. S. Luigi

Gonzaga, Orbassano, Italy

Site Status

Ospedale S. Antonio Abate

Via Pastori, 4, Gallarate, VA, Italy

Site Status

Presidio Ospedaliero Roberto Binaghi

Cagliari, , Italy

Site Status

Azienda Ospedaliera Universitaria Arcispedale Sant'Anna

Ferrara, , Italy

Site Status

Presidio Ospedaliero di Vaio Fidenza

Fidenza, , Italy

Site Status

Osp. Magg. Pol. Mangiagalli e Regina Elena - Fond. IRCCS

Milan, , Italy

Site Status

Az. Osp. Niguarda Ca' Granda

Milan, , Italy

Site Status

Presidio Ospedaliero di Montichiari

Montichiari, , Italy

Site Status

IRCCS Neurologico C. Mondino

Pavia, , Italy

Site Status

Az. Osp. Ospedale Consorziale e Policlinico

Piazza Giulio Cesare, 11 Bari, , Italy

Site Status

Az. Osp. Ospedale S. Martino - Università degli Studi

Via Antonio de Toni, 5, Genova, , Italy

Site Status

Ist. Neurol. Mediterraneo Neuromed

Via Atinense, 18, Pozzilli, , Italy

Site Status

Ospedali Riuniti Umberto I - GM Lancisi - G.Salesi

Via Conca, 71, Torrette Di Ancona, , Italy

Site Status

Osp. Clinicizzato Colle dell'Ara - Università G. D'Annunzio

Via Dei Vestini, 5 Chieti, , Italy

Site Status

Azienda Ospedaliera Sant'Andrea - Università La Sapienza

Via Di Grottarossa, 1035/1039, Roma, , Italy

Site Status

Azienda Ospedaliera di Padova - Università degli Studi

Via Giustiniani, 2, Padova, , Italy

Site Status

Az. Osp. Universitaria Policlinico Tor Vergata

Via Montpellier, 1, Roma, , Italy

Site Status

Ospedale San Raffaele - IRCCS

Via Olgettina, 48/60, Milano, , Italy

Site Status

Policlinico - Università degli Studi Federico II

Via Pansini, 5, Napoli, , Italy

Site Status

Istituto di Scienze Neurologiche Università di Catania

Via Santa Sofia, 78, Catania, , Italy

Site Status

Ospedale Bellaria Maggiore

Via Toscana Nazionale, 17/19, Bologna, , Italy

Site Status

Azienda Ospedaliera Careggi - Università degli Studi

Viale Giovan Battista Morgagni, 85, Firenze, , Italy

Site Status

Hospital Fernando Fonseca

Amadora, , Portugal

Site Status

Hospitais da Universidade de Coimbra

Av. Dr. Bissaya Barreto, Coimbra, , Portugal

Site Status

Hospital Sto. António dos

Capuchos, , Portugal

Site Status

Hospital de São João

Porto, , Portugal

Site Status

Hospital de S. Bernardo

Rua Camilo Castelo Branco, Setubal, , Portugal

Site Status

National Cancer Center, 809 Madu 1-dong, Ilsan-gu

Kyunggi, Goyang, South Korea

Site Status

Samsung Medical Center

Seoul, Korea, South Korea

Site Status

Yonsei Univ. Med. Center,Severance Hospital, 134 Shinchon-dong, Suedaemoon-ku

Seoul, , South Korea

Site Status

Kyung Pook National University Hospital

Taegu, , South Korea

Site Status

Complejo Hospitalario Carlos Haya

Avda. Carlos Haya, S/n, Málaga, , Spain

Site Status

Hospital Universitario Virgen Macarena

Avenida Dr. Fedriani, 3, Sevilla, , Spain

Site Status

Ciutat Sanitaria I, Universitaria De Bellvitge, c/o Feixa Llarga, Hospitalet de Llobregat

Barcelona, , Spain

Site Status

Hospital de Basurto

Bilbao, , Spain

Site Status

Hospital Clinico San Carlos

C/ Dr. Martin Lagos, S/n, Madrid, , Spain

Site Status

Unitat de Neuroimmunologia Clinica, Hospital Vall d'Hebron

EUI-planta 2, Pg. Vall d'Hebron 119-29, Barcelona, , Spain

Site Status

Puerta de Huerro Univeristy Hospital

San Martin de Porres, 4, Madrid, , Spain

Site Status

Hospital Universitario La Fe.

Valencia, , Spain

Site Status

Universitätsspital Zuerich

Neurologische Klinik, Frauenklinikstrasse 26, Zuerich, , Switzerland

Site Status

Universitätsspital Basel, Neurochirugishen Poliklinik

Petersgraben 4, Basel, , Switzerland

Site Status

Novartis

Investigational Site, , United Kingdom

Site Status

Charing Cross Hospital

London, , United Kingdom

Site Status

The Walton Centre for Neurology and Neurosurgery

Lower Lane, Fazakerly, Liverpool, , United Kingdom

Site Status

Norfolk & Norwich University Hospital

Norwick, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada Egypt France Germany Greece Hungary Italy Portugal South Korea Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L; TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016 May;87(5):468-75. doi: 10.1136/jnnp-2015-310597. Epub 2015 Jun 25.

Reference Type DERIVED
PMID: 26111826 (View on PubMed)

Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon beta-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.

Reference Type DERIVED
PMID: 25876473 (View on PubMed)

Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses. Adv Ther. 2014 Oct;31(10):1072-81. doi: 10.1007/s12325-014-0154-4. Epub 2014 Sep 23.

Reference Type DERIVED
PMID: 25245812 (View on PubMed)

Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul;120(7):1432-9. doi: 10.1016/j.ophtha.2012.12.040. Epub 2013 Mar 24.

Reference Type DERIVED
PMID: 23531349 (View on PubMed)

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.

Reference Type DERIVED
PMID: 21571593 (View on PubMed)

Twiss J, Doward LC, McKenna SP, Eckert B. Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Health Qual Life Outcomes. 2010 Oct 11;8:117. doi: 10.1186/1477-7525-8-117.

Reference Type DERIVED
PMID: 20937112 (View on PubMed)

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

Reference Type DERIVED
PMID: 20089954 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.msclinicaltrials.com

Fingolimod clinical trials information website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CFTY720D2302E1

Identifier Type: OTHER

Identifier Source: secondary_id

CFTY720D2302

Identifier Type: -

Identifier Source: org_study_id